Trial Information
Patient Registry: VIDAZA® in Patients With MDS, CMML or AML
Inclusion Criteria:
- Patients with MDS, CMML, and AML
- Who begin with or already have received treatment with VIDAZA®
- Who are willing to provide informed consent
Exclusion Criteria:
- Due to the non-interventional design of this program there are no specific exclusion
criteria.
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Response evaluation
Outcome Description:
hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration
Safety Issue:
No
Principal Investigator
Richard Greil, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Universitätsklinik für Innere Medizin III der PMU Salzburg
Authority:
Austria: Ethikkommission
Study ID:
AGMT_Vidaza Register
NCT ID:
NCT01595295
Start Date:
February 2009
Completion Date:
Related Keywords:
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- CMML
- MDS
- AML
- registry
- Vidaza
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Leukemia, Myelomonocytic, Chronic
- Myelodysplastic Syndromes
- Preleukemia
- Leukemia, Myelomonocytic, Acute